Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

Core Insights - Werewolf Therapeutics announced new clinical data from the Phase 1/1b trial of WTX-124, a conditionally activated IL-2 molecule, at the 2024 ASCO Annual Meeting [1][2] - The trial aims to evaluate WTX-124 in patients with advanced or metastatic solid tumors who have previously failed checkpoint inhibitor therapy [2][3] Clinical Trial Results - WTX-124 demonstrated clinical activity with three objective responses, including one durable confirmed complete response [3][4] - The recommended dose for expansion (RDE) for WTX-124 monotherapy was set at 18 mg administered intravenously every two weeks [6] - The combination of WTX-124 with pembrolizumab was well-tolerated, showing enhanced immune activation in tumors [3][10] Future Development Plans - The company has opened three expansion arms for WTX-124 in advanced or metastatic renal cell carcinoma, cutaneous melanoma, and cutaneous squamous cell carcinoma [6] - Ongoing dose escalation studies for WTX-124 in combination with pembrolizumab are planned, with an RDE expected to be selected in Q3 2024 [6] - The company intends to engage with regulators regarding potential registrational pathways for WTX-124, including accelerated approval strategies [6] Presentation and Webcast - The findings will be presented in a poster session at ASCO and a webcast is scheduled for June 3, 2024, to review the clinical results [1][7]